 HEIDELBERG, Germany, Sept. 08, 2021 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress. 